Company Performance - Novo Nordisk started 2025 as Europe's most valuable listed firm [1] - Obesity drug competition and profit downgrades have led to the stock facing its worst year on record [1] Leadership & Strategy - The situation puts pressure on Novo Nordisk's new leader to engineer a turnaround [1]